Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Quintessence Biosciences
Quintessence Biosciences is a biopharmaceutical company developing protein-based therapeutics to fight cancer.
Sector
Subsector
Location
total rounds
total raised
Covagen
Covagen is a biopharmaceutical company that develops protein-based therapeutics for the treatment of inflammatory diseases and cancer..
Sector
Subsector
Location
total rounds
total raised
Allakos
Allakos develops antibody-based therapeutics to treat diseases associated with dysregulation of the T-helper type 2 immune response.
Sector
Subsector
Location
total rounds
total raised
VBL THERAPEUTICS
VBL Therapeutics is a clinical stage biotech company that develops innovative treatments for cancer and immune-inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds13
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.01.2024. Their latest round Post-IPO Equity
Co-Investors
Investors9
Number of lead investors
Number of investors
New Enterprise Associates
NEA is a global venture capital firm that helps entrepreneurs build innovative businesses in technology and healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Robert Garland
Dr. Garland joined NEA in 2003 and invests in biopharmaceuticals and medical devices. He is a director of 3-V Biosciences, Cardioxyl Pharmaceuticals, Trevena, Inc., and Zyngenia, Inc. Prior to NEA, in addition to clinical practice at the University of California, San Francisco (UCSF), he was with McKinsey & Company’s Pharmaceutical & Medical Products and Corporate Finance & Strategy practices. At McKinsey, Dr. Garland worked with biotech, pharmaceutical, medical device, diagnostics, and private equity clients to evaluate investments, formulate product and corporate strategies and build businesses. Dr. Garland completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at UCSF and received his MBA and MPH from the University of California, Berkeley, his MD from Baylor College of Medicine, and his BS in EE/Bioengineering from Rice University.
current job
Qianhai Ark
Qianhai Ark
count Of Investments
Kleiner Perkins
Kleiner Perkins is a venture capital firm that invests in early-stage, incubation and growth companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Beth Seidenberg
Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO. Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
current job
People
Founders2
Lucas Pelkmans
Lucas Pelkmans is the Full Professor & Ernst Hadorn Chair at University of Zurich .
current job
organization founded
Lucas Pelkmans
Urs Greber
Urs Greber, PhD co-founded 3-V Biosciences, Inc. in 2006. Mr. Greber has been an Associate Professor for Cell Biology, Institute of Zoology at University of Zürich since 2003 and served as its Assistant Professor since 1995. He was awarded Swiss Talent for Academic Research and Teaching (START) Fellow at the Institute of Zoology in 1995. In 1991 he was a postdoctoral Research Associate at the Yale University School of Medicine in Connecticut. Prior to that, Mr. Greber served as a Postdoctoral Research Assistant of L. Gerace, Department of Cell and Molecular Biology, Scripps Research Institute, La Jolla, CA. His prime areas of interest focus on viral pathogens: ubiquitous, affecting all forms of life. He is elucidating how viruses trick the surveillance system of the host to overcome the dynamic host restrictions during entry, by employing high frequency live cell imaging and powerful computational approaches as well as viral genetics in combination with established cell biological and biochemical techniques.
current job
organization founded
Urs Greber
Employee Profiles19
Dena M. Minning
Vice President of Translational Medicine
Activity
Recent News9
The graph reveals the ratio (%) of positive news articles in a chosen time range